Your browser doesn't support javascript.
loading
Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna, Kiyoshi; Asakura, Keiichi; Araki, Seiichi; Ando, Hiroyuki; Kazusa, Katsuyuki; Kitaguchi, Takashi; Kunimatsu, Takeshi; Suzuki, Shinobu; Miyamoto, Norimasa.
Affiliation
  • Takasuna K; Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan. Electroni
  • Asakura K; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Discovery Research Labs., Nippon Shinyaku Co., Ltd., Kyoto, Japan.
  • Araki S; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Safety Research Department, ASKA Pharmaceutical Co., Ltd., Kanagawa, Japan.
  • Ando H; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Safety Research Laboratories, Ono Pharmaceutical Co., Ltd., Fukui, Japan.
  • Kazusa K; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Drug Safety Research Laboratories, Astellas Pharma Inc., Osaka, Japan.
  • Kitaguchi T; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Discovery Research, Mochida Pharmaceutical Co., Ltd., Shizuoka, Japan.
  • Kunimatsu T; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Preclinical Research Laboratories, Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan.
  • Suzuki S; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Pharmacokinetics and Non-Clinical Safety Dept., Nippon Boehringer Ingelheim Co., Ltd., Hy
  • Miyamoto N; Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee, Non-Clinical Evaluation Expert Committee, TF2, Japan; Consortium for Safety Assessment using Human iPS Cells (CSAHi): HEART team, Japan; Biopharmaceutical Assessments Core Function Unit Medicine Development Center Eisai Co., L
J Pharmacol Toxicol Methods ; 83: 42-54, 2017.
Article in En | MEDLINE | ID: mdl-27646297
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arrhythmias, Cardiac / Action Potentials / Myocytes, Cardiac / Drug-Related Side Effects and Adverse Reactions / Induced Pluripotent Stem Cells / Models, Cardiovascular Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Pharmacol Toxicol Methods Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2017 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arrhythmias, Cardiac / Action Potentials / Myocytes, Cardiac / Drug-Related Side Effects and Adverse Reactions / Induced Pluripotent Stem Cells / Models, Cardiovascular Type of study: Prognostic_studies Limits: Humans Language: En Journal: J Pharmacol Toxicol Methods Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2017 Document type: Article Country of publication: United States